Class-sparing regimens for initial treatment of HIV-1 infection.

  title={Class-sparing regimens for initial treatment of HIV-1 infection.},
  author={Sharon A. Riddler and Richard Haubrich and A Gregory Dirienzo and Lynne Peeples and William G. Powderly and Karin L. Klingman and Kevin W Garren and Tania George and James F. Rooney and Barbara Brizz and Umesh Lalloo and R. L. Murphy and Susan S Swindells and Diane V. Havlir and John W Mellors},
  journal={The New England journal of medicine},
  volume={358 20},
BACKGROUND The use of either efavirenz or lopinavir-ritonavir plus two nucleoside reverse-transcriptase inhibitors (NRTIs) is recommended for initial therapy for patients with human immunodeficiency virus type 1 (HIV-1) infection, but which of the two regimens has greater efficacy is not known. The alternative regimen of lopinavir-ritonavir plus efavirenz may prevent toxic effects associated with NRTIs. METHODS In an open-label study, we compared three regimens for initial therapy: efavirenz… CONTINUE READING